BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Telerik Inc.//Sitefinity CMS 14.4//EN
BEGIN:VTIMEZONE
TZID:Mountain Standard Time
BEGIN:STANDARD
DTSTART:20251102T020000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=11
TZNAME:Mountain Standard Time
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20250301T020000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYHOUR=2;BYMINUTE=0;BYMONTH=3
TZNAME:Mountain Daylight Time
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Experts in lymphomas\, plasma cell disorders\, myeloproliferati
 ve neoplasms\, acute myeloid leukemia\, myelodysplastic syndrome\, and coa
 gulation disorders will provide exciting updates from ASH 2019 with a focu
 s on the latest treatment advances relevant to your clinical practice. The
  day will include presentations\, case reviews\, and interactive question 
 and answer sessions.\nBy the end of the review\, attendees will be better 
 equipped to: Identify which patients with hematologic malignancy may benef
 it from specific targeted therapies. Recognize myriad of presentations of 
 patients with hematologic malignancy. Identify higher risk patients with h
 ematologic malignancy and know best available therapies for these patients
 . Recognize best current approach to patients requiring more aggressive tr
 eatments. Prescribe individualized plans for patients with hematologic mal
 ignancies based on specific disease characteristics (genetics\, molecular 
 markers). Manage complications of hematologic malignancies in an outpatien
 t setting.
DTEND:20200201T213000Z
DTSTAMP:20260609T085439Z
DTSTART:20200201T143000Z
LOCATION:
SEQUENCE:0
SUMMARY:Review of 2019 American Society of Hematology Annual Meeting 
UID:RFCALITEM639165920799871699
X-ALT-DESC;FMTTYPE=text/html:Experts in lymphomas\, plasma cell disorders\,
  myeloproliferative neoplasms\, acute myeloid leukemia\, myelodysplastic s
 yndrome\, and coagulation disorders will provide exciting updates from ASH
  2019 with a focus on the latest treatment advances relevant to your clini
 cal practice. The day will include presentations\, case reviews\, and inte
 ractive question and answer sessions.<br />\nBy the end of the review\, at
 tendees will be better equipped to: Identify which patients with hematolog
 ic malignancy may benefit from specific targeted therapies. Recognize myri
 ad of presentations of patients with hematologic malignancy. Identify high
 er risk patients with hematologic malignancy and know best available thera
 pies for these patients. Recognize best current approach to patients requi
 ring more aggressive treatments. Prescribe individualized plans for patien
 ts with hematologic malignancies based on specific disease characteristics
  (genetics\, molecular markers). Manage complications of hematologic malig
 nancies in an outpatient setting.
END:VEVENT
END:VCALENDAR